Weight Loss & Metabolic Health
Evidence-based guides to GLP-1 medicines, dual- and triple-agonist research, obesity treatment developments and metabolic-health questions.
SemaglutideGLP-1 medicine research and regulatory context.TirzepatideDual GIP/GLP-1 research and approved uses.RetatrutideInvestigational triple-agonist research.Semaglutide vs. TirzepatideCompare mechanisms, evidence and approved indications.Retatrutide vs. TirzepatideCompare investigational and approved treatment evidence.
What this section covers
We distinguish between brand-name drugs, active ingredients and investigational compounds. A medicine may be FDA approved for one indication but not another, and an investigational compound should not be presented as an approved treatment. Articles link to FDA, ClinicalTrials.gov and peer-reviewed research where available.